Astrana HealthASTH -1.26%87 Debt-to-EBITDA is 5.19 as of Mar. 2026, which is 124% above its 10-year median of 2.32. GuruFocus rates ASTH with a GF Score™ of 87/100 and a GF Value™ of $82.67 (Significantly Undervalued). The stock has 8 warning signs investors should review. Among 477 Healthcare Providers & Services companies, Astrana Health ranks worse than 82.6% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Astrana Health's Debt-to-EBITDA or its related term are showing as below:
ASTH'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.24 Med: 2.32 Max: 8.76
Current: 6.54
During the past 13 years, the highest Debt-to-EBITDA Ratio of Astrana Health was 8.76. The lowest was -1.24. And the median was 2.32.
ASTH's Debt-to-EBITDA is ranked worse than 82.6% of 477
companies
in the Healthcare Providers & Services industry
Industry Median: 2.22
vs ASTH: 6.54
Astrana Health (NAS:ASTH) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Astrana Health Debt-to-EBITDA Related Terms
Astrana Health Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Astrana Health's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Astrana Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astrana Health Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Astrana Health's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Astrana Health's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Astrana Health (ASTH) has a Debt-to-EBITDA of 5.19 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Astrana Health. This is 124% above median its historical median of 2.32. According to the industry distribution chart, Astrana Health ranks #394 out of 477 companies in the Healthcare Providers & Services industry, placing it in the top 82.6%.
Is Astrana Health's Debt-to-EBITDA too high?
Astrana Health's current Debt-to-EBITDA of 5.19 is 124% above median its 10-year median of 2.32. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.22. Astrana Health's value of 5.19 is 133.8% above this industry median. Based on the distribution chart, Astrana Health ranks #394 out of 477 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Astrana Health has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Astrana Health's Debt-to-EBITDA compare to SGRY and SEM?
According to the Healthcare Providers & Services industry distribution chart, Astrana Health ranks #394 out of 477 companies for Debt-to-EBITDA. This places Astrana Health in the lower half of its industry. The industry median Debt-to-EBITDA is 2.22. Astrana Health's value of 5.19 is 133.8% above this benchmark. While the company's 10-year median is 2.32 vs. the industry median of 2.22, Astrana Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.22, based on 477 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astrana Health's current Debt-to-EBITDA of 5.19 is 133.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Astrana Health. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astrana Health's current Debt-to-EBITDA is 5.19, which is 124% above median its own 10-year median of 2.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astrana Health stock overvalued right now?
Based on GuruFocus' analysis, Astrana Health (ASTH) is currently considered Significantly Undervalued. The stock's GF Value™ is $82.67, compared to a current price of $49.17 — trading 40.5% below its estimated fair value. The current Debt-to-EBITDA is 5.19, which is 124% above median its 10-year median of 2.32 and 133.8% above the Healthcare Providers & Services industry median of 2.22. Astrana Health's overall GF Score™ is 87/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Astrana Health (ASTH), the current Debt-to-EBITDA is 5.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astrana Health (ASTH) Overvalued in 2026?
Based on GuruFocus' analysis, Astrana Health stock appears to be undervalued.
The current stock price of $49.17 is trading 40.5% below its estimated GF Value™ of $82.67.
GuruFocus considers Astrana Health to be Significantly Undervalued.
Key valuation signals for ASTH:
Debt-to-EBITDA: 5.19 (124% above median its 10-year median of 2.32)
GF Value™: $82.67 vs. price of $49.17 (40.5% below fair value)
Industry Position: 133.8% above the Healthcare Providers & Services median (#394 of 477)
No single metric tells the full story. See the ASTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
87GF Score
Get the complete analysis for ASTH
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASTH has been successfully added to your 
